SEQUA.BR

Sequana Medical NV [SEQUA.BR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SEQUA.BR Stock Summary

In the News

SEQUA.BR Financial details

Company Rating
-
Market Cap
45.37M
Income
-56.7M
Revenue
1.36M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
05 Sep 2024
P/E
-3.12
Forward P/E
-
PEG
-0.48
P/S
129.17
P/B
-44.62
P/C
-
P/FCF
-4.23
Quick Ratio
1.25
Current Ratio
1.52
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.22
EPS next Y
-
EPS next Q
-
EPS this Y
-9.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0%
Revenue last 5Y
-6.01%
Revenue Q/Q
-14.67%
EPS Q/Q
-12.31%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-118%
ROE
2093%
ROC
-2.61%
Gross Margin
78%
Oper. Margin
-3077%
Profit Margin
-3334%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.36-5.18
52W High
-87.78%
52W Low
-38.9%
RSI
71
Rel Volume
6.04
Avg Volume
108.07K
Volume
653.15K
Perf Week
0%
Perf Month
24.69%
Perf Quarter
-
Perf Half Y
-6.43%
-
-
-
-
Beta
0.834
-
-
Volatility
0%, 0.04%
Prev Close
0%
Price
0.611
Change
0%

Something similar

Top by Market Cap
EMBASSY.NS
1YD.DE
BRK-A
VOO
META
Same Sector
4157.TWO
JNJ
EHC
002462.SZ
RPHM
Same Price Range
2258.HK
XPL
ALMAR.PA
SOL.MC
2317.HK
Similar Market Cap
SMAL
KONT.ST
FLQS
SHAG
AP

Company Profile

Healthcare Medical - Devices
  • Volume Average 108.07K
  • Market Capitalization 45.37M
  • Employee 70
  • CEO Mr. Ian Crosbie
  • Headquarters Gent,BE
  • IPO Date 2019-02-11
  • Website https://www.sequanamedical.com

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.